Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of September 2025, with a specific reporting date of September 26, 2025. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon is a global leader in consumer health with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data provided relates to specific share transactions executed by executives:
- Transaction Type: Acquisition of Ordinary Shares and American Depositary Shares (ADS) via dividend reinvestment.
- Transaction Date: September 23, 2025.
- Share Price (GBP): £3.31963 per Ordinary Share.
- Share Price (USD): $8.99986 per ADS.
- Trading Venues: London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document strictly details routine share acquisitions by senior management resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Executive Participation: Six senior executives participated in dividend reinvestment transactions on September 23, 2025: Dawn Allen (CFO), Keith Choy (President, Asia Pacific), Filippo Lanzi (President, EMEA and LATAM), Brian McNamara (CEO), Edward Petter (Chief Corporate Affairs Officer), and Tamara Rogers (Chief Marketing Officer).
- Transaction Nature: All reported transactions were acquisitions of shares via dividend reinvestment, indicating no open-market selling by these executives during this period.
- Volume Details:
- Brian McNamara acquired 5,693.57 Ordinary Shares and 2,026.51 ADSs.
- Keith Choy acquired 3,749.42 Ordinary Shares.
- Filippo Lanzi acquired 2,356.42 Ordinary Shares.
- Tamara Rogers acquired 1,906.13 Ordinary Shares.
- Dawn Allen acquired 1,186.71 Ordinary Shares.
- Edward Petter acquired 576.54 Ordinary Shares.
- Limitation of Scope: This filing does not provide quarterly or annual financial performance data; investors should refer to Form 20-F or earnings releases for financial results.